Skip to main content
. Author manuscript; available in PMC: 2008 Jan 1.
Published in final edited form as: J Hepatol. 2007 Feb 22;47(1):23–30. doi: 10.1016/j.jhep.2007.01.027

Fig. 2.

Fig. 2

A) Median alanine aminotransferase (ALT) decline from baseline in sustained virological responders (SVRs) and nonresponders (NRs) during the first four weeks of pegylated interferon and ribavirin treatment. B) Changes in log10HCV RNA in SVRs, end of treatment responders (ETRs) and NRs during the first 28 days of pegylated interferon and ribavirin treatment. C) Median HCV RNA decline from baseline in SVRs and NRs during the first 28 days of pegylated interferon and ribavirin treatment. Dotted line indicates level of assay detection for HCV RNA (29 IU/ml).